Federal State Unitary Enterprise (FSUE) St. Petersburg Scientific Research Institute of Vaccines and Serums and Biopharmaceutical Plant under Federal Medical Biological Agency of Russia has been conducting research and development and producing preventive, diagnostic, and therapeutic medications for more than 120 years. SPbSRIVS has highly skilled research and production staff and uses state-of-the-art technology to offer products that meet all existing global standards. SPbSRIVS is a major supplier of therapeutic, preventive, and diagnostic medications to the markets in Russia and the CIS.


Our key products are vaccines against influenza and herpes, tuberculosis allergen (tuberculin), preparations used in the diagnosis of tuberculosis, syphilis, intestinal and coccal infections, forensic serums. Some of the most important medications that we produce are:

  • Seasonal flu vaccine
  • Bleomycetin hydrochloride
  • Rubomycin
  • Doxorubicin
  • Interferon
  • Collalisin
  • Terrylithine


The last three years have witnessed an increase in the value of government contracts won by SPbSRIVS from 200 mln rubles in 2012 to 680 mln rubles in 2015 and a more than fourfold increase in the sales revenue. This revenue growth was made possible by the adoption of new technology and a complete upgrade of the immunobiological production line, which was done on a tight schedule, due to existing obligations under government contracts.


We will be glad to partner with developers of new medicines, product distributors, and institutional customers. We believe that our partnership will contribute to the effectiveness of healthcare and public health. V.P. Trukhin, Director of FSUE SPbSRIVS under FMBA of Russia


Protection of future generations through the prevention of viral diseases and the constant search for new ways to improve the quality of life and health in Russia and around the world.

Support and promotion of vaccination as the most effective way to prevent viral diseases and epidemics.


The history of SPbSRIVS dates back to 1938, when the serum and vaccine department at IEM was reorganized into the Leningrad Research Institute of Vaccines and Serums of the USSR Ministry of Health.

During the World War 2 and the 900-day blockade of Leningrad, the Institute continued to produce and supply antiviral drugs not only to Leningrad, army troops defending Leningrad, and the Baltic Fleet, but also to the Red Army units and regions of Russia's Northwest outside the Nazi forces encircling Leningrad.

In the postwar years, the production of antiviral drugs was taken to a new technological level and up-to-date technology was adopted.


The strategic goal pursued by FGUP SPbSRIVS is to retain a leading position in the biomedical industry both in Russia and abroad. Only by achieving the set goal, we will ensure the sustainable development of the Company and achieve the optimal return on investment. In this endeavor, we carefully select our partners and consistently strive to maintain the highest standards of doing business.